HUMANITAS MIRASOLE SPA
Clinical Trials
8
Trial Phases
2 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (8 trials with phase data)ā¢ Click on a phase to view related trials
Open Label Extension of TUDCA-ALS Study
- Conditions
- Amyotrophic Lateral Sclerosis
- Interventions
- First Posted Date
- 2023-03-03
- Last Posted Date
- 2023-03-03
- Lead Sponsor
- Humanitas Mirasole SpA
- Target Recruit Count
- 184
- Registration Number
- NCT05753852
- Locations
- š§šŖ
Katholieke Universiteit Leuven, Leuven, Belgium
š«š·Centre Hospitalier Universitaire de Bordeaux, Bordeaux, France
š«š·Centre Hospitalier Universitaire Limoges, Limoges, France
Safety and Efficacy of TUDCA as add-on Treatment in Patients Affected by ALS
- Conditions
- Amyotrophic Lateral Sclerosis (ALS)
- Interventions
- Drug: Placebo
- First Posted Date
- 2019-01-11
- Last Posted Date
- 2023-07-10
- Lead Sponsor
- Humanitas Mirasole SpA
- Target Recruit Count
- 337
- Registration Number
- NCT03800524
- Locations
- š§šŖ
Katholieke Universiteit Leuven, Leuven, Belgium
š«š·Centre Hospitalier Universitaire de Bordeaux, Bordeaux, France
š«š·Centre Hospitalier Universitaire Limoges, Limoges, France
News
High Blood Eosinophils and FeNO Levels Predict Better Dupilumab Response in Moderate-to-Severe Asthma
ā¢ Post-hoc analysis of LIBERTY ASTHMA QUEST trial reveals patients with elevated blood eosinophils and FeNO levels show significantly higher odds of achieving clinical remission with dupilumab treatment. ā¢ Clinical remission, defined by four criteria including no exacerbations, no symptoms, no oral corticosteroids, and stable lung function, was achieved in 38.3% of dupilumab-treated patients versus 26.2% in placebo group. ā¢ Patients with blood eosinophil counts ā„150 cells/ĀµL and FeNO levels ā„20 ppb showed the strongest response to dupilumab, with adjusted odds ratio of 2.63 for achieving clinical remission.